Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Salvador Martin Algarra"'
Autor:
José Manuel Aramendía, Jose Manuel Ordoñez, Javier Aristu, Salvador Martin Algarra, Rafael Martínez Monje, Esteban Salgado, Maria Gonzalez Cao, Antonio Brugarolas
Publikováno v:
American Journal of Clinical Oncology. 25:480-484
The purpose of this study was to evaluate the efficacy and tolerance of combined irinotecan and vinorelbine in previously treated patients with stage IIIB and IV non-small-cell lung cancer (NSCLC). Thirty-three patients with NSCLC (7 stage IIIB and 2
Autor:
Antonio Brugarolas, C. Beltran, José Javier Aristu, M. Moreno, Salvador Martin Algarra, Joseba Rebollo, Ignacio Azinovic, Rafael Martínez-Monge, José María López-Picazo, Oscar A Fernández, José Manuel Aramendía
Publikováno v:
American Journal of Clinical Oncology. 25:347-353
Multidisciplinary treatment in high-risk breast cancer improves survival and local control. The feasibility and patterns of failure after several induction and high-dose consolidation regimens of chemotherapy were evaluated in this study. Between Nov
Autor:
José Ramón Azanza, Almudena Gomez-Guiu, Salvador Martin Algarra, Jose Luis Perez-Gracia, Anabel del Barrio, Miguel Angel Campanero, María J. Blanco Prieto, José María López-Picazo, Francisco Guillén Grima, Alfonso Gurpide, Belén Sádaba
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 2, p e89747 (2014)
PLoS ONE, Vol 9, Iss 2, p e89747 (2014)
Background Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even t
Autor:
Mariano Provencio Pulla, Joan Manel Gasent Blesa, Salvador Martin Algarra, Emilio González, Vicente Alberola Candel
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 11(1)
Platinum resistant ovarian cancer is a current challenge in Oncology. Current approved therapies offer no more of a 20% of response. New therapeutic options are urgently needed. Patients were treated with the combination of Pemetrexed 500 mg/m2 d1 an